Acceptability: total withdrawals · acute mania
Lithium showed no clear difference in acceptability: total withdrawals compared with all antimanic agents (high certainty).
1 finding from 1 review
Adverse events · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Efficacy: response (continuous) Change in YMRS (ITT‐LOCF) from baseline to end of study · acute mania
1 finding from 1 review
Response rate at 3 weeks (primary efficacy outcome) · Adults (aged 18 and over) with acute mania
Valproate leads to higher response rate at 3 weeks (primary efficacy outcome) compared with placebo (high certainty).
1 finding from 1 review
Dropout · Children and adolescents with acute mania
Valproate showed no clear difference in dropout rate ‐ All‐cause At 4‐6 weeks (secondary acceptability… compared with placebo (low certainty).
1 finding from 1 review
Response rate at 3 weeks (primary efficacy outcome) · Adults (aged 18 and over) with acute mania
Valproate showed no clear difference in response rate at 3 weeks (primary efficacy outcome) compared with lithium (moderate certainty).
1 finding from 1 review
Primary outcome 3: Adverse events · Adults (aged 18 and over) with acute mania
Valproate showed no clear difference in number of participants with any adverse event at 2‐4 weeks (primary… compared with lithium (low certainty).
1 finding from 1 review
Adverse effects: 1. Sedation · Adults (aged 18 and over) with acute mania
Valproate showed no clear difference in individual adverse events ‐ Sedation At 3 weeks (secondary… compared with lithium (low certainty).
1 finding from 1 review
Change in symptom severity at 3 weeks (secondary efficacy outcome) · Adults (aged 18 and over) with acute mania
1 finding from 1 review
Dropout · Adults (aged 18 and over) with acute mania
Valproate showed no clear difference in dropout rate ‐ All‐cause At 2‐4 weeks (secondary acceptability… compared with lithium (moderate certainty).
1 finding from 1 review
Response rate at 8 weeks (primary efficacy outcome) · Children and adolescents with acute mania
It is very uncertain whether valproate changes response rate at 8 weeks (primary efficacy outcome) compared with lithium (very low certainty).
1 finding from 1 review
Number of participants with any adverse event (primary tolerability outcome) · Children and adolescents with acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events: somnolence/sedation · Children and adolescents with acute mania
It is very uncertain whether valproate changes individual adverse events ‐ Sedation At 8 weeks (secondary… compared with lithium (very low certainty).
1 finding from 1 review
Change in symptom severity of mania rating scale at 8 weeks (secondary efficacy outcome) · Children and adolescents with acute mania
1 finding from 1 review
Primary outcome 3: Adverse events · Adults (aged 18 and over) with acute mania
Valproate probably leads to higher number with any adverse event after 3 weeks (primary tolerability… compared with placebo (moderate certainty).
1 finding from 1 review
Dropout · Children and adolescents with acute mania
It is very uncertain whether valproate changes dropout rate ‐ All‐cause At 8 weeks (secondary acceptability outcome) compared with lithium (very low certainty).
1 finding from 1 review
Response rate at 3 weeks (primary efficacy outcome) · Adults (aged 18 and over) with acute mania
Valproate showed no clear difference in response rate at endpoint at 3 weeks (primary efficacy outcome) compared with olanzapine (low certainty).
1 finding from 1 review
Number of participants with any adverse event (primary tolerability outcome) · Adults (aged 18 and over) with acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects: 1. Sedation · Adults (aged 18 and over) with acute mania
Valproate leads to lower adverse events ‐ Sedation At 3‐12 weeks (secondary tolerability… compared with olanzapine (high certainty).
1 finding from 1 review
Change in symptom severity at 3 weeks (secondary efficacy outcome) · Adults (aged 18 and over) with acute mania
1 finding from 1 review